TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03754400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Antibiotics, nutrition and supportive treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Antibiotics, nutrition and supportive treatment
Study: NCT01193478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 3 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 10 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days
Study: NCT00857155

Intervention type: OTHER
Group type: OTHER
Intervention: Clopidogrel withdraw prior to CABG
Description: Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
Study: NCT00489866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active drug.
Study: NCT01193478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, 30 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, up to 90 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, up to 90 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: tablet, oral, up to 90 mg once daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: tablet, oral, once daily for 3 days
Study: NCT04692974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone application and smart watch
Description: Mobile phone application prompts
Study: NCT05463393

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/
Description: The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Xanthohumol - prenylated chalcone extracted from female inflorescences of hop cones (Humulus lupus). Hop-RXn™, BioActive-Tech Ltd, Lublin, Poland; http://xanthohumol.com.pl/
Description: The appropriate dose of Xanthohumol was solved in 1 mL of propylene glycol
Study: NCT00975000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Possible sequential doses are 30, 60, 90, 120, and 180 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally following the same dosing regimen as the experimental arm.
Study: NCT02047929

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Shared Decision Making (SDM) Toolkit
Description: A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Shared Decision Making (SDM) Toolkit
Description: A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
Study: NCT01869959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2405319
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2405319
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2405319
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02903849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drafting Motivational Messages
Description: Write down three motivating messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drafting Motivational Messages
Description: Write down three motivating messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Reminders
Description: Receive standard reminders at three points during the challenge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Reminders
Description: Receive reminders containing the messages they leave themselves at three points during the challenge
Study: NCT03686085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone 3 mg
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal tablet
Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study: NCT00703222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
Description: SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^6 cells/m2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
Description: SJNB-JF-IL2 and SJNB-JF-Lptn at 1 x 10\^7 cells/m2~SKNLP at 1 x 10\^7 cells/m2
Study: NCT01388036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esmolol
Description: consecutive infusions of esmolol and normal saline (placebo)
Study: NCT01717300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib 100 mg
Description: 100 mg tablet, oral, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for anacetrapib 100 mg
Description: Placebo tablet, orally, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib 100 mg
Description: Placebo tablet, orally, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib 25 mg
Description: 25 mg tablet, oral, once daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for anacetrapib 25 mg
Description: Placebo tablet, orally, once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib 25 mg
Description: Placebo tablet, orally, once daily for 24 weeks
Study: NCT03504501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: oral application prior to transcranial magnetic stimulation intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: oral application prior to transcranial magnetic stimulation intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: oral application prior to transcranial magnetic stimulation intervention
Study: NCT01322061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
Study: NCT02020356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
Study: NCT01153971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1
Study: NCT02156570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Description: Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg \<75kg, 1200mg \>/= 75 kg) Treatment will be for 6 weeks in all participants.
Study: NCT00759369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water prescription
Description: Water prescription in 12 to 16 equally divided doses
Study: NCT00795886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAPAMYCIN
Description: Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
Study: NCT04901182

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Description: the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Description: the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: the effect of consuming diets on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Description: the effect of consuming white sesame soy milk smoothie (WS), Chicken shitake smoothie (CS) vs. Ensure on the swallowing capacity by using Flexible Endoscopic Evaluation of Swallowing (FEES)
Study: NCT05620186

Intervention type: OTHER
Group type: OTHER
Intervention: PROSPECT
Description: PROficiency Based StePwise Endovascular Curricular Training

Intervention type: OTHER
Group type: OTHER
Intervention: PROSPECT
Description: PROficiency Based StePwise Endovascular Curricular Training
Study: NCT05577819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-pyrophosphate Scintigraphy
Description: Cardiac Imaging Technique used to diagnose Transthyretin Cardiac Amyloidosis by use of 15 mCi of 99mTC-Pyrophosphate tracer
Study: NCT02980965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
Description: Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil, epirubicin, cyclophosphamide, docetaxel
Description: Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
Study: NCT04460222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational Thromboelastometry to guide blood product transfusion pre invasive procedure
Description: Rotational Thromboelastometry will be performed pre procedure and blood component will be transfused if~* EXTEM CT more than 80 sec then FFP will be transfused at 15 ml/kg MCF less than 35 mm then Platelet will be transfused at 10 ml/kg~* FIBTEM MCF less than 7 mm then Cryoprecipitate will be transfused at 5 ml/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional transfusion methods to guide blood product transfusion pre invasive procedure
Description: Transfusion will be given If INR: 1.5 - 2.5 FFP will be transfused at 10 ml/kg If Platelet Count is 20,000/mm3-50,000/mm3 Platelet will be transfused at 10 ml/kg If Fibrinogen \< 80 mg/dl Cryoprecipitate will be transfused at 5 ml/kg
Study: NCT00152217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 (S-1)
Description: 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
Study: NCT02690675

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified formula milk
Description: One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified formula milk
Description: One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
Study: NCT04168177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Patient controlled analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP
Description: erector spinae plane block
Study: NCT02481895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-neurocognitive module
Description: The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
Study: NCT02829749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord beating heart mitral valve implantation
Description: The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
Study: NCT02276456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Appointment- early vs standard
Description: Patient will undergo early follow-up (within 7 days of discharge) of discharge
Study: NCT04314453

Intervention type: OTHER
Intervention: percutaneous endoscopic lumbar discectomy
Description: Resection of the hypertrophied faceted joints, osteophyte formation and ligamentum flavum (LF) hypertrophy, with or without disc protrusion for degenerative spinal stenosis.
Study: NCT00103740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 5 mg zoledronic acid in 5 mL of sterile water for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to zoledronic acid
Description: 5 mL of sterile water for infusion
Study: NCT02713776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
Study: NCT02451553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02060071

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Blood test

Intervention type: OTHER
Group type: OTHER
Intervention: Blood test
Description: Blood test
Study: NCT01596894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin + Metronidazole
Description: Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Study: NCT03686917

Intervention type: OTHER
Intervention: CHAT-P
Description: Survey
Study: NCT00103740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 30mg oral tablets overencapsulated to match the placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to risedronate
Description: oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D supplements
Description: Calcium and vitamin D supplements were supplied
Study: NCT03722602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation after stroke
Description: The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
Study: NCT00872404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: 20mg/kg/3 weeks
Study: NCT04796142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medication reconciliation
Description: medication reconciliation
Study: NCT01445379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg